Hossein-Javaheri Nariman, O'Connor Katie, Steinhart Hillary, Deshpande Amol, Maxwell Cynthia, Huang Vivian, Tandon Parul
Department of Internal Medicine, University at Buffalo-State University of New York, Buffalo, New York, USA.
Division of Gastroenterology and Hepatology, University Health Network/Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5G 1X5Canada.
J Can Assoc Gastroenterol. 2023 Nov 25;7(2):204-211. doi: 10.1093/jcag/gwad049. eCollection 2024 Apr.
Many patients with inflammatory bowel disease (IBD) may use cannabis for relief of symptoms. During pregnancy, however, cannabis exposure may be associated with adverse pregnancy outcomes. We aimed to determine the prevalence and perceptions of cannabis use in women with IBD.
Through recruitment at Mount Sinai Hospital and online platforms such as Twitter, women with IBD (age 18-45) were asked to complete anonymous surveys on demographics, cannabis use, perception of use during pregnancy, and discussing its use with healthcare providers (HCP). Categorical variables were reported as frequencies and compared across groups with the chi-square test.
One-hundred and two pregnant patients with IBD were included in this study, 19 (18.6%) reported using cannabis. Current users were more likely to report constant pain in the last 12 months and discuss its use with their HCP. Fifty-three (52.0%) women were unsure of the specific risks associated with cannabis use during pregnancy, and only 15 (14.7%) had ever discussed its use with their HCP. Those who had discussed cannabis use with their HCP were more likely to have prior IBD-related surgery, perceive its use unsafe during pregnancy, and be more likely to be using cannabis.
Many women with IBD report uncertainty of the risks of cannabis use during pregnancy and the majority have never discussed cannabis use with their providers. With the increasing legalization of cannabis in many jurisdictions, it is imperative patients and healthcare providers discuss the risks and benefits of its use, particularly during vulnerable times such as pregnancy.
许多炎症性肠病（IBD）患者可能会使用大麻来缓解症状。然而，在怀孕期间接触大麻可能与不良妊娠结局有关。我们旨在确定IBD女性中大麻使用的患病率和看法。
通过在西奈山医院和推特等在线平台招募，邀请年龄在18 - 45岁的IBD女性完成关于人口统计学、大麻使用、怀孕期间对使用大麻的看法以及与医疗保健提供者（HCP）讨论其使用情况的匿名调查。分类变量以频率报告，并通过卡方检验在各组之间进行比较。
本研究纳入了102名患有IBD的孕妇，其中19名（18.6%）报告使用过大麻。当前使用者更有可能报告在过去12个月中持续疼痛，并与他们的HCP讨论其使用情况。53名（52.0%）女性不确定怀孕期间使用大麻的具体风险，只有15名（14.7%）曾与她们的HCP讨论过其使用情况。那些与HCP讨论过大麻使用情况的人更有可能有过与IBD相关的手术，认为怀孕期间使用大麻不安全，并且更有可能正在使用大麻。
许多IBD女性报告对怀孕期间使用大麻的风险存在不确定性，并且大多数人从未与她们的医疗服务提供者讨论过大麻使用情况。随着大麻在许多司法管辖区的合法化程度不断提高，患者和医疗服务提供者必须讨论其使用的风险和益处，特别是在怀孕期间等脆弱时期。
